PLoS ONE (Jan 2020)

The clinical value of peripheral immune cell counts in pancreatic cancer.

  • Osama Abu-Shawer,
  • Mohammad Abu-Shawer,
  • Abdullah Shurman,
  • Ali Lattouf,
  • Ayman Haimour,
  • Omar Hamdan,
  • Razan Mansour,
  • Tamer Altamimi,
  • Maysa Al-Hussaini

DOI
https://doi.org/10.1371/journal.pone.0232043
Journal volume & issue
Vol. 15, no. 6
p. e0232043

Abstract

Read online

BackgroundElevated neutrophil-lymphocyte ratio (NLR) is linked to poor overall survival (OS) in pancreatic cancer. We aim to investigate the association of the various hematologic markers, in particular NLR among others, with distant metastases, a common feature in pancreatic cancer.MethodsClinical data from 355 pancreatic cancer patients managed at King Hussein Cancer Center (Amman-Jordan) have been reviewed. We examined the relationship between absolute neutrophil count (ANC), absolute lymphocyte count (ALC), absolute eosinophilic count (AEC), absolute monocytic count (AMC), NLR, monocyte to lymphocyte ratio (MLR) and platelet to lymphocyte ratio (PLR) with the presence of baseline distant metastases and OS. Receiver Operating Characteristic (ROC) curve analysis was plotted to identify the NLR optimum cutoff value indicative of its association with distant metastases.ResultsOn univariate and multivariate analyses patients whom on presentation had high NLR (≥3.3) showed more baseline distant metastases compared to patients with low NLR (ConclusionThis study presents additional evidence of the association of some of the hematologic markers; in particular ANC, NLR, AMC, and MLR, with baseline distant metastases and poor outcome in pancreatic cancer. Whether these immune phenomena can help in identifying patients at higher risk for the subsequent development of distant metastases is unknown.